Skip to main content
OpenTrials

Clinical trial condition

Liver Diseases

Explore clinical trials studying Liver Diseases. Study availability and eligibility vary by location and protocol.

8,421 public trials 1,317 recruiting studies
Refine in advanced search Browse all conditions

Liver Diseases trial results

Completed

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • University Of Connecticut Health Center Farmington, Connecticut, United States
  • Local Institution Concord, New South Wales, Australia
  • Local Institution Randwick, New South Wales, Australia
  • Local Institution Porto Alegre Rs, Rio Grande do Sul, Brazil
View all 67 locations
View Trial Details
Completed

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +9 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • West Coast Clinical Trials, LLC Costa Mesa, California, United States
  • University of California Antiviral Research Center (AVRC) San Diego, California, United States
  • Indiana University Medical Center Indianapolis, Indiana, United States
View all 23 locations
View Trial Details
Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

NCT00115908

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
  • John Hunter Hospital New Lambton Heights, New South Wales, Australia
  • Westmead Hospital Westmead, New South Wales, Australia
View all 87 locations
View Trial Details
Completed

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00743795

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Anaheim, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • San Clemente, California, United States
View all 72 locations
View Trial Details
Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Anaheim, California, United States
  • GSK Investigational Site Arcadia, California, United States
View all 227 locations
View Trial Details
Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site La Jolla, California, United States
View all 191 locations
View Trial Details

Related conditions